VR Adviser’s CASI Pharmaceuticals CASI Stock Holding History

VR Adviser’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-987,259	Closed	-$839K	–	34
2025 Q4	$839K	Hold	987,259	–	–	0.04%	27
2025 Q3	$1.64M	Hold	987,259	–	–	0.09%	33
2025 Q2	$1.16M	Hold	987,259	–	–	0.09%	30
2025 Q1	$2.13M	Hold	987,259	–	–	0.18%	31
2024 Q4	$2.79M	Hold	987,259	–	–	0.19%	33
2024 Q3	$6.08M	Buy	987,259 +875,573	+784%	+$5.66M	0.32%	35
2024 Q2	$614K	Buy	+111,686	New	+$347K	0.04%	35

Other funds holding CASI

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

VR Adviser's CASI Position: Q1 2026 in Review

VR Adviser sold out of CASI Pharmaceuticals (CASI) in Q1 2026, closing a stake of 987,259 shares — an estimated $839K sold.

VR Adviser first reported a position in CASI in Q2 2024 and held it in 7 quarters. The position peaked at $6.08M in Q3 2024. 1 fund tracked by Wall St. Rank holds CASI as of Q1 2026.

VR Adviser reported no remaining CASI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
VR Adviser sold 987,259 CASI Pharmaceuticals shares in Q1 2026, an estimated $839K.
VR Adviser first reported a position in CASI Pharmaceuticals in Q2 2024 and held it in 7 quarters.
VR Adviser's CASI Pharmaceuticals position peaked at $6.08M in Q3 2024.
1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.